Lung Cancer | Specialty

Liquid Biopsies Making Impact in Lung Cancer, Other Tumor Types

February 5th 2017

The noninvasive testing that has long been the goal of solid tumor analysis is making its presence felt in lung cancer, and other malignancies likely will not be far behind, experts say. Although many potential uses for liquid biopsies are envisioned, much work remains to be done to establish the clinical utility of these tests.

Dr. Papadimitrakopoulou on Role of Immunotherapy in Lung Cancer

February 4th 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the subset of patients with lung cancer which would derive the most benefit from immunotherapy.

Dr. Jackman on Benefits of Liquid Biopsies in Lung Cancer

February 3rd 2017

David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the benefits of liquid biopsies for patients with lung cancer.

Dr. Socinski on Challenges Facing Immunotherapy Combinations

February 3rd 2017

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses challenges facing immunotherapy combinations in patients with non–small cell lung cancer (NSCLC).

Dr. Weiss on Disease-Control Rate of Immunotherapy for Lung Cancer

February 1st 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy as treatment to control disease for patients with lung cancer.

EC Approves Frontline Pembrolizumab for PD-L1+ Metastatic NSCLC

February 1st 2017

The European Commission has expanded the indication for pembrolizumab to include the frontline treatment of patients with metastatic non–small cell lung cancer that expresses PD-L1 on ≥50% of cells and does not harbor an EGFR or ALK mutation.

Future Directions for ALK+ NSCLC

January 31st 2017

Emerging ALK/ROS1 TKIs for NSCLC

January 31st 2017

Upfront Use of Second-Generation TKIs in ALK+ NSCLC

January 31st 2017

ASCEND-4: Upfront Ceritinib in ALK-Rearranged NSCLC

January 31st 2017

ALK Inhibitor Sequencing in NSCLC

January 31st 2017

Mutation Testing to Guide ALK TKI Selection in NSCLC

January 31st 2017

Choosing Second-Line Therapy for ALK+ NSCLC

January 31st 2017

Alectinib for Relapsed/Refractory ALK+ NSCLC

January 31st 2017

Ceritinib Alternative Dosing for ALK+ NSCLC

January 31st 2017

Experience with Ceritinib for ALK+ NSCLC

January 31st 2017

Ceritinib and Alectinib in Relapsed ALK+ NSCLC

January 31st 2017

Crizotinib Resistance in ALK+ NSCLC

January 31st 2017

The Evolution of ALK/ROS1-Targeted TKIs

January 31st 2017

Anti-PD-1/PD-L1 Immunotherapy in Lung Cancer: Update From the ESMO 2016 Congress

January 31st 2017

Lung cancer is the leading cause of cancer-related deaths among men and women in the United States, despite being the second most commonly diagnosed cancer.